Simeprevir

Simeprevir

SCHEMBL1070885

COc1ccc2c(OC3CC4C(=O)NC5(C(=O)NS(=O)(=O)C6CC6)CC5C=CCCCCN(C)C(=O)C4C3)cc(-c3nc(C(C)C)cs3)nc2c1C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ CTSS P25774 1/20 1.00
▸ CTSB P07858 1/20 0.66
▸ ADRB3 P13945 1/20 0.46
▸ ADRA2B P18089 1/20 0.46
▸ ADRA2C P18825 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Simeprevir SCHEMBL2229194 1.00 CTSS (1.00) CTSSCTSBADRB3ADRA2BADRA2C
Simeprevir SCHEMBL18539068 1.00 CTSS (1.00) CTSSCTSBADRB3ADRA2BADRA2C
Simeprevir SCHEMBL6876363 1.00 CTSS (1.00) CTSSCTSBADRB3ADRA2BADRA2C
Simeprevir SCHEMBL829744 1.00 CTSS (1.00) CTSSCTSBADRB3ADRA2BADRA2C
Simeprevir SCHEMBL25465130 1.00 CTSS (1.00) CTSSCTSBADRB3ADRA2BADRA2C
Simeprevir SCHEMBL12445256 1.00 CTSS (1.00) CTSSCTSBADRB3ADRA2BADRA2C
Simeprevir SCHEMBL25465866 1.00 CTSS (1.00) CTSSCTSBADRB3ADRA2BADRA2C
Simeprevir SCHEMBL826061 1.00 CTSS (1.00) CTSSCTSBADRB3ADRA2BADRA2C
Simeprevir SCHEMBL18537915 1.00 CTSS (1.00) CTSSCTSBADRB3ADRA2BADRA2C
Simeprevir SCHEMBL18697017 1.00 CTSS (1.00) CTSSCTSBADRB3ADRA2BADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2271936-B1 IN VITRO METHOD TO DETERMINE WHETHER A DRUG CANDIDATE ACTIVE AGAINST A TARGET PROTEIN IS ACTIVE AGAINST A VARIANT OF SAID PROTEIN VALNEVA (FR) 2015-05-06 — — EP disclosed
EP-2271936-A1 IN VITRO METHOD TO DETERMINE WHETHER A DRUG CANDIDATE ACTIVE AGAINST A TARGET PROTEIN IS ACTIVE AGAINST A VARIANT OF SAID PROTEIN Vivalis (FR) 2011-01-12 — — EP disclosed
WO-2009112592-A1 IN VITRO METHOD TO DETERMINE WHETHER A DRUG CANDIDATE ACTIVE AGAINST A TARGET PROTEIN IS ACTIVE AGAINST A VARIANT OF SAID PROTEIN VIVALIS (FR) 2009-09-17 — — WO disclosed
Send feedback